Tai Tsung Board Approves Exclusive Licensing Agreement for U101 with Subsidiary TCM Life Science Inc.

Release Date: 1150703 Statement Date: 1150702 Statement Time: 212026 Company Code: 4169 Company Name: Tai Tsung Subject: The company's board of directors has resolved to approve the signing of an exclusive licensing agreement for U101 with its subsidiary TCM Life Science Inc. Applicable Clause: Clause 20 Event Date: 1150702 Details: 1. Name and nature of the subject matter (if preferred shares, specify issuance terms such as dividend rate): Global clinical research and development, registration, manufacturing, and commercialization rights for U101 2. Event Date: 115/7/2 ~ 115/7/2 3. Board Approval Date: July 2, 115 (2026) 4. Other Approval Dates: Not applicable 5. Transaction quantity, unit price, and total transaction amount: Total contract authorization amount (including development and sales milestone payments) is USD 750 million 6. Counterparty and its relationship with the company (if the counterparty is a natural person and not a related party, name disclosure may be omitted): TCM Life Science Inc. is a U.S.-established subsidiary wholly owned (100%) by the company 7. If the counterparty is a related party, disclose the reason for selecting such party, previous transferor, relationship among previous transferor, company, and counterparty, transfer date, and amount: Reason for selecting related party: Based on corporate resource allocation and R&D strategy considerations Previous transferor: Not applicable Relationship among previous transferor, company, and counterparty: Not applicable Transfer date and amount: Not applicable 8. If the ownership of the subject matter was held by a related party of the company within the past five years, disclose the related party's acquisition and disposal date, price, and relationship with the company at the time: Not applicable 9. Matters related to the disposal of receivables (including types of collateral attached to disposed receivables; if receivables are from related parties, disclose the party's name and book value of receivables disposed): Not applicable 10. Gain (or loss) from disposal (not applicable if acquiring securities) (deferred gains should be listed with recognition details): Not applicable 11. Delivery or payment terms (including payment periods and amounts), contractual restrictions, and other important provisions: The contract shall only become effective upon the subsidiary's confirmed receipt of external funding or sublicense revenue. The subsidiary will make milestone and royalty payments progressively during the U101 development and commercialization phases. 12. Decision-making method for this transaction, reference basis for price determination, and decision-making body: The company's Audit Committee and Board of Directors, after thorough discussion, resolved to approve the transaction, referring to the U101 valuation report issued by an independent valuation agency and the accountant's opinion on price reasonableness. 13. Net asset value per share of the securities-acquiring or -disposing company: Not applicable 14. Cumulative holdings (including this transaction) of securities, amount, ownership ratio, and restricted rights (e.g., pledge status) to date: Not applicable 15. Proportion of securities investments listed under Article 3 of the 'Asset Acquisition and Disposal Handling Rules for Publicly Issued Companies' (including this transaction) to the company's total assets and equity attributable to owners of the parent in the latest financial statements, and the amount of working capital in the latest financial statements (Note 2): Not applicable 16. Broker and brokerage fees: Not applicable 17. Specific purpose or use of acquisition or disposal: Based on corporate resource allocation and R&D strategy considerations. 18. Dissenting directors' opinions on this transaction: None 19. Is this transaction a related-party transaction: Yes 20. Date of acknowledgment by supervisors or approval by Audit Committee: July 2, 115 (2026) 21. Did the accountant issue a non-reasonable opinion on this transaction: No 22. Name of accounting firm: Shuo Yi United Certified Public Accountants 23. Accountant's name: You Shang搃7 24. Accountant's license number: Financial Supervisory Commission Certificate No. 7707 25. Does this involve a change in business model: No 26. Explanation of business model change: Not applicable 27. Transaction status with the counterparty in the past year and expected in the next year: Not applicable 28. Source of funds: Not applicable 29. Previous date of material information release regarding the same event: Not applicable 30. Other disclosures: None